Mark C. Schneyer, Executive Vice President, Chief Financial Officer at Acadia Pharmaceuticals Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Mark C. Schneyer has served as ACADIA's Executive Vice President and Chief Financial Officer since December 2021. He joined the company in May 2020 as Senior Vice President, Business Development and Chief Business Officer and served as interim CFO from September to December 2021. He oversees strategic finance, investor relations, accounting, business development, information technology and technical operations. Before ACADIA he was Vice President, Business Development for Pfizer's Upjohn division and spent nearly a decade in Pfizer's Worldwide Business Development organization, following 14 years as an investment banker at Lazard. He earned a B.S. in economics from the Wharton School of the University of Pennsylvania.
Roles
Acadia Pharmaceuticals Inc.
Executive Vice President, Chief Financial Officer · Current role
December 2021–present
ACADIA Pharmaceuticals
Executive Vice President and Chief Financial Officer
December 2021 - present
ACADIA Pharmaceuticals
Interim Chief Financial Officer
September 2021 - December 2021
ACADIA Pharmaceuticals
Senior Vice President, Business Development and Chief Business Officer
May 2020 - December 2021
Pfizer Inc.
Vice President, Business Development (Upjohn division)
2019 - May 2020
Pfizer Inc.
Worldwide Business Development, various roles
2011 - 2019
Lazard
Investment banker
1996 - 2010
Fixed Compensation
FY 2025
Salary
$546,428
ComponentAnnual base salary earned in FY2025
All other compensation
$28,174
Component401(k) match, insurance premiums, and other perquisites
Total compensation
$3,119,408
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$303,341
Target Opportunity
—
PlanAnnual cash bonus under the corporate incentive plan